MIST II PFO-Migraine Trial With BioSTAR® Bioabsorbable Septal Repair Implant
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00283738|
Recruitment Status : Unknown
Verified January 2008 by NMT Medical.
Recruitment status was: Active, not recruiting
First Posted : January 30, 2006
Last Update Posted : January 25, 2008
|Condition or disease||Intervention/treatment||Phase|
|Migraine Aura Patent Foramen Ovale||Device: BioSTAR Septal Repair Implant System Procedure: Sham Procedure||Phase 2 Phase 3|
During the last five years, transcatheter and surgical closure of PFO in the cyrptogenic stroke and TIA population has grown in frequency world-wide. Observational retrospective reports, from both single and multi-center experiences of over 400 patients, suggest Patent Foramen Ovale (PFO) closure to reduce the risk of recurrent migraine events in these populations may be beneficial, particularly for those patients in the migraine with aura subgroup. Although none of these reports are from prospective, randomized, controlled trials, the reports are compelling enough in their totality to support further investigation of a well defined group in a prospective manner. The patients reported in these studies were brought to PFO closure with no expectation of their procedure having any impact on their migraine. In fact, in many cases, the discovery of a history of migraine was not made until well after the PFO closure procedure.
This clinical trial will prospectively compare the safety and effectiveness of PFO closure with the BioSTAR device to a control arm. Patients will be followed one year post-implant.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||610 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||A Prospective, Multi-Center, Double-Blinded, Placebo-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With the BioSTAR Septal Repair Implant to Reduce Refractory Migraine Headache With Aura.|
|Study Start Date :||February 2006|
|Estimated Study Completion Date :||March 2008|
|Active Comparator: 1||
Device: BioSTAR Septal Repair Implant System
Placebo Comparator: 2
Procedure: Sham Procedure
- Efficacy: Migraine reduction rates during analysis period.
- Safety: Incidence of Major Adverse Cardiac Events (MACE) one year post-implantation.
- Efficacy:Change in number of attacks from baseline period compared to analysis phase.
- Safety: Device success during index procedure without procedural complication.
- Incidence of major AEs during index procedure and post-procedure as they relate to the device and protocol specified medications.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00283738
|United States, Connecticut|
|New England Center for Headache|
|Stamford, Connecticut, United States, 06902|
|United States, Washington|
|Swedish Medical Center|
|Seattle, Washington, United States, 98104|
|Principal Investigator:||Mark Reisman, MD||Swedish Medical Center, Seattle, WA|
|Principal Investigator:||Stewart J. Tepper, MD||Director of the New England Center for Headache|